Table 1.
Baseline characteristics of the study population.
| Characteristics | Patients (n = 333) |
|---|---|
| Age | |
| Mean (SD) | 54.0 (13.9) |
| Median [Min, Max] | 53.9 [26.1, 86.2] |
| BMI category | |
| <25 | 161 (48.3%) |
| 25–30 | 122 (36.6%) |
| >30 | 50 (15.0%) |
| Type of breast surgery | |
| Mastectomy | 91 (27.3%) |
| BCS | 187 (56.2%) |
| Mastectomy + reconstruction | 55 (16.5%) |
| Receptor status | |
| Triple negative | 47 (14.1%) |
| HER2 positive | 38 (11.4%) |
| HR positive and HER2 negative | 225 (67.6%) |
| Unknown | 23 (6.9%) |
| Primary tumor stage | |
| pT0 | 29 (8.7%) |
| pT1 | 187 (56.2%) |
| pT2 | 69 (20.7%) |
| pT3 | 9 (2.7%) |
| pT4 | 0 (0%) |
| pTis | 33 (9.9%) |
| pTmi | 6 (1.8%) |
| Regional lymph nodes stage | |
| pN0 | 249 (74.8%) |
| pN1 | 66 (19.8%) |
| pN2 | 14 (4.2%) |
| pN3 | 4 (1.2%) |
| Hormonal therapy | |
| No | 149 (44.7%) |
| Yes | 184 (55.3%) |
| Chemoimmunotherapy | |
| No | 196 (58.9%) |
| Yes | 137 (41.1%) |
| Axillary treatment | |
| SLNB/RISAS | 231 (69.4%) |
| ALND | 35 (10.5%) |
| SLNB/RISAS + Rtx | 27 (8.1%) |
| ALND + Rtx | 40 (12.0%) |
Abbreviations: ALND, axillary lymph node dissection; BCS, breast-conserving surgery; BMI, body mass index; HR, hormone receptor; RISAS, radioactive iodine seed localization in the axilla with sentinel node procedure; Rtx, radiotherapy; SLNB, sentinel lymph node biopsy. Note: HER2 positive, if HER2 is positive; HR-positive, estrogen receptor+ and/or progesterone receptor+ and HER2−; triple-negative, estrogen receptor- and progesterone receptor- and HER2−.